Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2025 Earnings Call Transcript February 10, 2026 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $1.86, expectations were $1.81. Rebecca: ...

COLUMBUS, Ohio (WCMH) — Girls at Hilltonia Middle School got a hands-on experience in health care science Tuesday. After ...

Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? Over the past ...

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.

A South Korean life sciences company plans to open a genetic testing lab in North Austin, a move that could create up to 200 jobs. Last week, the Austin City Council approved a $200,000 economic ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

The new facility will cost $137 million and will house 18 research labs, four teaching labs, a 300-seat lecture hall, and ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript February 9, 2026 Anavex Life Sciences Corp. beats ...

Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA.

A professor and chair of UAMS’ Department of Orthopaedic Surgery, C. Lowry Barnes was selected as one of four finalists in a ...